- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04981119
Solide Tumoranalyse für HLA-Heterozygotieverlust (LOH) und Leukapherese für die Herstellung von CAR-T-Zellen (BASECAMP-1)
Eine Beobachtungsstudie zur Gewinnung von solidem Tumorgewebe von Probanden mit primärer chirurgischer Resektion und Leukapherese für die Herstellung von CAR-T-Zelltherapien
Objective:
To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment.
Design:
This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
Studienübersicht
Status
Bedingungen
- Krebs
- Darmkrebs
- Bauchspeicheldrüsenkrebs
- Eierstocktumoren
- Eierstockkrebs
- NSCLC
- Nicht-kleinzelligem Lungenkrebs
- Mesotheliom
- Mesotheliom, bösartig
- Bauchspeicheldrüsenkrebs
- Eierstockkrebs
- Solider Tumor, Erwachsener
- CRC
- Dreifach negativer Brustkrebs (TNBC)
- Kopf-Hals-Plattenepithelkarzinom HNSCC
- Mesotheliom; Lunge
- Nierenzellkarzinom (Nierenkrebs)
Intervention / Behandlung
Detaillierte Beschreibung
Background:
Human Leukocyte Antigen (HLA) is a protein on the outside of cells that allows the immune system to recognize it's own cells as normal and leave them alone or respond if infected with a virus or bacteria, or a tumor cell. HLA might not be expressed normally on cancer cells. This may be why cancer can grow undetected by the immune system and is referred to as a tumor escape mechanism. Tumor escape can occur for many reasons, but one reason is Loss of Heterozygosity (LOH). LOH is the loss of one of the genes that encodes HLA protein. A2 Biotherapeutics, Inc. (A2 Bio) is developing therapies to recognize, target, and kill cancer cells that do not express HLA normally, and minimize any damage to normal cells that express normal HLA.
Once participants are identified as having LOH on their tumors, apheresis, a procedure to separate and collect white blood cells will be performed. It is the first required step in manufacturing CAR T-cell therapy. The collected T cells will be stored for patients that are likely to benefit from CAR T-cell therapy during their disease care.
Study Design:
Approximately 3000 participants will be screened for part 1 of the study, including HLA typing, approximately 1500 participants will have NGS testing on their tumor samples and be followed for up to 2 years on the study, and up to 500 participants will be screened for part 2 of the study and enrolled if eligible and apheresed and be followed for up to 2 years on the study.
Participants will be screened (Part 1) for HLA type, and based on results, participants will have archived tumor tissue tested by next generation sequencing (NGS) and be followed for up to 2 years. Based on the tumor NGS results, participants may be apheresed (Part 2) for Peripheral Blood Mononuclear Cell (PBMC) collection to store their T cells for a future interventional study upon relapse.
Each participant will proceed through the following study periods:
- Screening (Part 1 and 2)
- Enrollment (Apheresis)
- Post Apheresis safety follow-up (Day 7)
- Two-year long term follow-up
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Gilbert, Arizona, Vereinigte Staaten, 85234
- Banner Health
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Mayo Clinic Hospital
-
-
California
-
Duarte, California, Vereinigte Staaten, 90101
- City of Hope
-
La Jolla, California, Vereinigte Staaten, 92093
- University of California San Diego
-
Palo Alto, California, Vereinigte Staaten, 94304
- Stanford University
-
Santa Monica, California, Vereinigte Staaten, 90404
- UCLA Medical Center
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Mayo Clinic Jacksonville
-
Tampa, Florida, Vereinigte Staaten, 33136
- Moffitt Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital/Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic Rochester
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Washington University
-
-
New York
-
New York, New York, Vereinigte Staaten, 10016
- NYU Langone Medical Center
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- The Ohio State University Comprehensive Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98109
- Fred Hutchinson Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Participants with Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PANC), mesothelioma, or Ovarian Cancer (OVAC) that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years, germline HLA-A*02 heterozygous, and have confirmed somatic LOH.
Beschreibung
Key Eligibility Criteria (additional criteria may apply) Part 1 Key Inclusion Criteria
1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), or Pancreatic Cancer (PANC), that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.
Part 1: Key Exclusion Criteria
- History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.
- Prior allogeneic stem cell transplant.
- Prior solid organ transplant.
Part 2 : Key Inclusion Criteria
- Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PANC), Mesothelioma, or Ovarian Cancer (OVAC) that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.
- Participants are germline HLA-A*02 heterozygous confirmed by HLA typing.
- Primary tumor tissue showing LOH of HLA-A*02 by NGS testing.
- Eastern Cooperative Oncology Group (ECOG) 0 or 1 performance status.
Part 2: Key Exclusion Criteria
- History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.
- Prior allogeneic stem cell transplant.
- Prior solid organ transplant.
- Participants who have received any cancer therapy on any investigational therapy for any indication, including but not limited to chemotherapy, small molecules, monoclonal antibodies, or radiotherapy (with bone marrow impact) within 2 weeks of planned apheresis or 3 half-lives, whichever is shorter.
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment necessitating specific treatment, or any major episode of infection requiring treatment with Intravenous (IV) antimicrobials (e.g., IV antibiotics) or hospitalization (relating to completion of antibiotic course).
- Has known active central nervous system metastases. Subjects with previously treated brain metastases may participate upon medical monitor agreement.
- In the Investigator's judgement, any other condition or reason the subject would not complete the required study visits and procedures, and follow up visits, or comply with the study requirements for participation.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of participants who can enroll in an A2 Biotherapeutics, Inc. CAR T-cell therapy study after undergoing apheresis
Zeitfenster: up to 2 years
|
Participants will be followed for their status of enrollment on an A2 Biotherapeutics, Inc. interventional study |
up to 2 years
|
|
Percentage of screened participants experiencing loss of heterozygosity (LOH) of HLA-A*02 identified by next generation sequencing
Zeitfenster: Screening
|
Percentage of participants experiencing LOH will be calculated based on NGS results |
Screening
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of enrolled participants who experience an adverse event (AE) related to apheresis
Zeitfenster: 7 days
|
Adverse events will be collected and monitored for relatedness to apheresis during the course of the study |
7 days
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienleiter: Eric W Ng, MD, FAAP, A2 Biotherapeutics Inc.
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C; TRACERx Consortium. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017 Nov 30;171(6):1259-1271.e11. doi: 10.1016/j.cell.2017.10.001. Epub 2017 Oct 26.
- Hamburger AE, DiAndreth B, Cui J, Daris ME, Munguia ML, Deshmukh K, Mock JY, Asuelime GE, Lim ED, Kreke MR, Tokatlian T, Kamb A. Engineered T cells directed at tumors with defined allelic loss. Mol Immunol. 2020 Dec;128:298-310. doi: 10.1016/j.molimm.2020.09.012. Epub 2020 Oct 1.
- Hwang MS, Mog BJ, Douglass J, Pearlman AH, Hsiue EH, Paul S, DiNapoli SR, Konig MF, Pardoll DM, Gabelli SB, Bettegowda C, Papadopoulos N, Vogelstein B, Zhou S, Kinzler KW. Targeting loss of heterozygosity for cancer-specific immunotherapy. Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):e2022410118. doi: 10.1073/pnas.2022410118.
- Perera J, Mapes B, Lau D, et al. Detection of human leukocyte antigen class I loss of heterozygosity in solid tumor types by next-generation DNA sequencing. J Immunother Cancer. 2019, 7(Suppl 1):P103
- Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822.
- Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, Duyvesteyn K, Haidari S, van Hoeck A, Onstenk W, Roepman P, Voda M, Bloemendal HJ, Tjan-Heijnen VCG, van Herpen CML, Labots M, Witteveen PO, Smit EF, Sleijfer S, Voest EE, Cuppen E. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019 Nov;575(7781):210-216. doi: 10.1038/s41586-019-1689-y. Epub 2019 Oct 23.
- Viale PH. The American Cancer Society's Facts & Figures: 2020 Edition. J Adv Pract Oncol. 2020 Mar;11(2):135-136. doi: 10.6004/jadpro.2020.11.2.1. Epub 2020 Mar 1. No abstract available.
- Hecht JR, Molina JR, Liechty K, Welling TH, Grierson PM, Patel SP, Kirtane K, Morelli MP, Locke FL, Maloney DG, Punekar SR, Nikiforow S, Lin Y, Ulrickson M, Specht JM, Lozac'hmeur A, Osterman CK, Garde RJ, Rangel GA, Ng EW, Welch JS, Tebbets JC, Go WY, Simeone DM. BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials. BMJ Oncol. 2026 Mar 27;5(1):e001033. doi: 10.1136/bmjonc-2025-001033. eCollection 2026.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des endokrinen Systems
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Männliche Urogenitalerkrankungen
- Nierenerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Darmerkrankungen
- Erkrankungen der Atemwege
- Neubildungen nach histologischem Typ
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Darmtumoren
- Rektale Erkrankungen
- Genitalerkrankungen, weiblich
- Lungenkrankheit
- Neoplasmen der endokrinen Drüse
- Erkrankungen der Bauchspeicheldrüse
- Neubildungen, Drüsen und Epithelien
- Adenokarzinom
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Darmerkrankungen
- Lungentumoren
- Eierstockerkrankungen
- Adnexerkrankungen
- Genitale Neubildungen, weiblich
- Gonadenstörungen
- Adenom
- Neubildungen, Mesothel
- Pleuraneoplasmen
- Hautkrankheiten
- Brusterkrankungen
- Urologische Neubildungen
- Karzinom
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Neoplasien der Brust
- Haut- und Bindegewebserkrankungen
- Mesotheliom, bösartig
- Neubildungen
- Kolorektale Neubildungen
- Eierstocktumoren
- Mesotheliom
- Neoplasmen der Bauchspeicheldrüse
- Karzinom, Nierenzelle
- Karzinom, nicht-kleinzellige Lunge
- Dreifach negative Brustneoplasmen
- Nierentumoren
- Therapeutika
- Entfernung von Blutkomponenten
Andere Studien-ID-Nummern
- A2B101-101
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .